Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Rat (Rattus) Antibodies:
anti-Mouse (Murine) Antibodies:
Go to our pre-filtered search.
Human Polyclonal AKR1C3 Primary Antibody for ELISA, WB - ABIN151439
Werner, Kulle, Sommerfeld, Riepe, Wudy, Hartmann, Merz, Döhnert, Bertelloni, Holterhus, Hiort: Testosterone synthesis in patients with 17β-hydroxysteroid dehydrogenase 3 deficiency. in Sexual development : genetics, molecular biology, evolution, endocrinology, embryology, and pathology of sex determination and differentiation 2012
Show all 2 Pubmed References
Human Polyclonal AKR1C3 Primary Antibody for FACS, WB - ABIN654117
Canzian, Cox, Setiawan, Stram, Ziegler, Dossus, Beckmann, Blanché, Barricarte, Berg, Bingham, Buring, Buys, Calle, Chanock, Clavel-Chapelon, DeLancey, Diver, Dorronsoro, Haiman, Hallmans, Hankinson, Hunter, Hüsing, Isaacs, Khaw, Kolonel, Kraft, Le Marchan: Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium. in Human molecular genetics 2010
Show all 6 Pubmed References
Human Polyclonal AKR1C3 Primary Antibody for ELISA, WB - ABIN1534617
Korzekwa, Szczepańska, Bogdaszewski, Nadolski, Malż, Giżejewski: Production of prostaglandins in placentae and corpus luteum in pregnant hinds of red deer (Cervus elaphus). in Theriogenology 2016
Human Polyclonal AKR1C3 Primary Antibody for WB - ABIN522092
Ebert, Kisiela, Wsól, Maser: Proteasome inhibitors MG-132 and bortezomib induce AKR1C1, AKR1C3, AKR1B1, and AKR1B10 in human colon cancer cell lines SW-480 and HT-29. in Chemico-biological interactions 2011
Human Polyclonal AKR1C3 Primary Antibody for WB - ABIN522094
Quiñones-Lombraña, Ferguson, Hageman Blair, Kalabus, Redzematovic, Blanco: Interindividual variability in the cardiac expression of anthracycline reductases in donors with and without Down syndrome. in Pharmaceutical research 2014
Data suggest that, in breast cancer cells, expression of HSD17B5 and expression of GRP78 (show HSPA5 Antibodies) (an apoptosis inhibitor) are strongly but negatively correlated; GRP78 (show HSPA5 Antibodies) knockdown decreases breast cancer cell viability whereas HSD17B5 knockdown increases cell viability and cell proliferation. (HSD17B5, 17-beta-hydroxysteroid dehydrogenase 5; GRP78 (show HSPA5 Antibodies), 78 kDa glucose-regulated protein (show HSPA5 Antibodies))
AKR1C3 is the primary enzyme and CBR1 (show CBR1 Antibodies) is a minor enzyme responsible for warfarin reduction in human liver cytosol.
the present study suggests that AKR1C1 (show DDH Antibodies), AKR1C2 (show AKR1C2 Antibodies), AKR1C3, and AKR1C4 (show AKR1C4 Antibodies) are closely associated with drug resistance to both CDDP and 5FU, and that mefenamic acid, an inhibitor of AKR1C, restores sensitivity through inhibition of drug-resistance in human cancer cells.
a variant in the promoter region of HSD17B5 related to fetal androgen synthesis influences the genital phenotype in 21-Hydroxylase Deficiency females.
Five common AKR1C3 polymorphisms were associated with decreased rates of exemestane catalysis.
If our these findings can be reproduced in larger homogeneous cohorts, a genetic stratification based on the AKR1C3 rs12529 single nucleotide polymorphism, can minimize androgen deprivation therapy-related health-related quality of life effects in prostate cancer patients
We identified strong associations between the studied AKR1C3 variants and UBC (show RPS27A Antibodies) risk. The homozygous variant genotype of rs12529 was found to be inversely associated with UBC (show RPS27A Antibodies), and rs1937920 was shown to be associated with increased risk of UBC (show RPS27A Antibodies). None of the genotypes were found to be significantly associated with tumor characteristics.
aldo-keto reductase 1C3-mediated prostaglandin D2 metabolism has a role in keloids
The results suggest that decreased expression of AKR1C3 may be involved in development of gastric cancer and can be restored by Sodium Butyrate.
AKR1C3 expression is elevated in prostate cancer cell lines and primary prostate cancer, suggesting a link between AKR1C3 levels and the epigenetic status in prostate cancer cells.
This gene encodes a member of the aldo/keto reductase superfamily, which consists of more than 40 known enzymes and proteins. These enzymes catalyze the conversion of aldehydes and ketones to their corresponding alcohols by utilizing NADH and/or NADPH as cofactors. The enzymes display overlapping but distinct substrate specificity. This enzyme catalyzes the reduction of prostaglandin (PG) D2, PGH2 and phenanthrenequinone (PQ), and the oxidation of 9alpha,11beta-PGF2 to PGD2. It may play an important role in the pathogenesis of allergic diseases such as asthma, and may also have a role in controlling cell growth and/or differentiation. This gene shares high sequence identity with three other gene members and is clustered with those three genes at chromosome 10p15-p14. Three transcript variants encoding different isoforms have been found for this gene.
aldo-keto reductase family 1, member C3 (3-alpha hydroxysteroid dehydrogenase, type II)
, prostaglandin F synthase
, aldo-keto reductase family 1 member C3 homolog
, 3-alpha hydroxysteroid dehydrogenase, type II
, 3-alpha-HSD type II, brain
, aldo-keto reductase family 1 member C3
, chlordecone reductase homolog HAKRb
, dihydrodiol dehydrogenase 3
, dihydrodiol dehydrogenase X
, indanol dehydrogenase
, testosterone 17-beta-dehydrogenase 5
, trans-1,2-dihydrobenzene-1,2-diol dehydrogenase
, type IIb 3-alpha hydroxysteroid dehydrogenase
, 20 alpha-hydroxysteroid dehydrogenase
, 20-alpha-hydroxysteroid dehydrogenase
, 20alpha-hydroxysteroid dehydrogenase
, aldo-keto reductase family 1 member C18
, aldo-keto reductase family 1, member C18
, 17-beta-HSD 5
, 17-beta-hydroxysteroid dehydrogenase type 5
, 3-alpha-HSD type 2
, 3-alpha-hydroxysteroid dehydrogenase type 2